↓ Read PDF
01 · ABSTRACT

Abstract

Background

Transthyretin Cardiac Amyloidosis (ATTR) is a type of restrictive cardiomyopathy, which typically manifests as Heart Failure with Preserved Ejection Fraction (HFpEF).

The presence of unexplained left ventricular hypertrophy (LVH) associated with HF and red flag manifestations could increase the diagnostic probability. However, the diagnostic prevalence of this triad by cardiac scintigraphy remains uncertain.

Methods

From August 1st to December 31st, 2021, 22 consecutive patients diagnosed with a HF (ejection fraction more than 40%), LVH with unexplained etiology and at least one red flag clinical manifestation, underwent pyrophosphate scintigraphy (99mTc-PYP). The patients were divided into two groups: “Positive” and “Negative” (as defined by grade 2 or 3 uptake). Multiple logistic models were made with variable 99mTC-PYP and explanatory variables.

Results

Among 22 patients, 15 had a positive 99mTc-PYP study for ATTR. The prevalence of ATTR using the triad of HFpEF, unexplained LVH and at least one red flag was 68% (CI 95%; 45-86%). Patients with 99mTc-PYP positive tended to be male, older, and with an aortic mean gradient and interventricular septum higher, as compared to the group with a negative study. The most frequent red flag clinical manifestations were proteinuria (55%) and pseudoinfarction pattern (55%). The presence of 2 or more red flags could increase the diagnostic probability of the test (OR 1.6 (CI95% 0.52-4.89).

Conclusions

The diagnostic probability of ATTR by 99mTc-PYP scan could increased when a clinical manifestation of a red flag was added to the suspected diagnosis of heart failure and left ventricular hypertrophy. The use of non-invasive techniques allows early identification and treatment of this underdiagnosed disease.

↓ Read PDF
02 · PUBLICATION RECORD

Article details

JournalMedical Research Archives
IssueVol 10 No 3 (2022): Vol.10 Issue 3 March 2022
SectionResearch Articles
Published31 March 2022
DOI10.18103/mra.v10i3.2739
ISSN2375-1924
03 · RIGHTS & REUSE

Rights & reuse

This article is published under a Creative Commons Attribution License (CC BY 3.0) and may be shared or distributed by anyone as long as attribution is given to the journal.

Authors & affiliations

MN

Mariano Ezequiel Napoli Llobera

Research fellowship of Heart Failure Disease Management Program, Division of Cardiology, Health Sciences North Hospital, Sudbury, Ontario - Canada.

LL

Lilia Luz Lobo Marquez

Medical Director of Heart Failure Disease and Pulmonary Hypertension, Division of Cardiology, Cardiology Institute, San Miguel de Tucuman, Tucuman - Argentina.

KK

Kari Kostiw

Clinical Manager of Heart Failure Disease Management Program, Division of Cardiology, Health Sciences North Hospital, Sudbury, Ontario - Canada.

DW

Dave Webster

Director Nuclear Medicine, Division of Cardiology, Health Sciences North Hospital, Sudbury, Ontario - Canada.

AC

Atilio Eugenio Costa Vitali

Medical Director of Heart Failure Disease Management Program, Division of Cardiology, Health Sciences North Hospital, Sudbury, Ontario - Canada.

Medical Research Archives

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Start your submission  ↗